Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00312650 | Doxil and Gemcitabine in Recurrent Ovarian Cancer | terminated | Phase 2 | 24 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Jan 12, 2015 | clinicaltrials |
| NCT00507741 | Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) | completed | Phase 2 | 49 | EndocyteINDUSTRY | 0 | Jan 7, 2015 | clinicaltrials |
| NCT00722592 |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)(PRECEDENT) |
| completed |
| Phase 2 |
| 162 |
| EndocyteINDUSTRY |
| 0 |
| Jan 7, 2015 |
| clinicaltrials |
| NCT00390611 | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | completed | Phase 2 | 85 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT01747239 | Cabazitaxel in Platinum Refractory Ovarian Cancer | terminated | Phase 2 | 4 | Vejle HospitalOTHER | 1 | Dec 4, 2014 | clinicaltrials |
| NCT02004093 | A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 149 | Hoffmann-La RocheINDUSTRY | 9 | Dec 4, 2014 | clinicaltrials |
| NCT00751205 | Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | completed | Phase 2 | 150 | BayerINDUSTRY | 6 | Oct 28, 2014 | clinicaltrials |
| NCT00928642 | Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 8 | Henry M. Jackson Foundation for the Advancement of Military MedicineOTHER | 1 | Oct 21, 2014 | clinicaltrials |
| NCT00868192 | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | completed | Phase 2 | 38 | Washington University School of MedicineOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT01481701 | A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | completed | Phase 2 | 90 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT01834469 | Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients(OV-AP-ICG-IV) | completed | Phase 1 / Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT01149434 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | terminated | Phase 1 / Phase 2 | 19 | University of UtahOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00477386 | Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | Indiana UniversityOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT02017678 | Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin | withdrawn | Phase 2 | 0 | Andrea McCartOTHER | 1 | Sep 17, 2014 | clinicaltrials |
| NCT00410462 | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma | unknown | Phase 2 | 118 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Aug 8, 2014 | clinicaltrials |
| NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | completed | Phase 2 | 64 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Aug 6, 2014 | clinicaltrials |
| NCT00004206 | Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer | unknown | Phase 2 | — | University of LeicesterOTHER | 1 | Jun 24, 2014 | clinicaltrials |
| NCT00418093 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2014 | clinicaltrials |
| NCT01163552 | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | completed | Phase 2 | 5 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jun 13, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00003449 | Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 35 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183794 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00083122 | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00093496 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT00126542 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00170677 | Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer | completed | Phase 2 | 194 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 14, 2014 | clinicaltrials |
| NCT00841191 | A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors | completed | Phase 1 / Phase 2 | 84 | Centocor, Inc.INDUSTRY | 5 | May 14, 2014 | clinicaltrials |
| NCT00919984 | Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer | terminated | Phase 2 | 22 | Korea Cancer Center HospitalOTHER | 1 | May 9, 2014 | clinicaltrials |
| NCT02132988 | Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer | unknown | Phase 2 | 110 | Mackay Memorial HospitalOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00436644 | Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | completed | Phase 2 | 18 | Mayo ClinicOTHER | 1 | Apr 16, 2014 | clinicaltrials |
| NCT00543049 | Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor | completed | Phase 2 | 73 | AGO Study GroupOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00086892 | Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 5 | Feb 14, 2014 | clinicaltrials |
| NCT00087087 | Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Feb 14, 2014 | clinicaltrials |
| NCT00504257 | Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma | completed | Phase 2 | 45 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00553683 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | unknown | Phase 1 / Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT01639885 | Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer(CHIP) | completed | Phase 1 / Phase 2 | 15 | Leiden University Medical CenterOTHER | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00003064 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 1 / Phase 2 | 30 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003560 | Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 2 | 40 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003718 | Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma | unknown | Phase 2 | 25 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT01131039 | Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Dec 20, 2013 | clinicaltrials |
| NCT00096239 | CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00021385 | Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer | unknown | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 18, 2013 | clinicaltrials |
| NCT00025441 | Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors | completed | Phase 2 | — | Societe Internationale d'Oncologie PediatriqueOTHER | 3 | Dec 4, 2013 | clinicaltrials |
| NCT01079832 | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2013 | clinicaltrials |
| NCT00617773 | Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 31 | Recepta BiopharmaINDUSTRY | 1 | Nov 26, 2013 | clinicaltrials |
| NCT00053833 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 2 | Nov 8, 2013 | clinicaltrials |
| NCT00004064 | Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | unknown | Phase 2 | 102 | AltaRexINDUSTRY | 2 | Nov 6, 2013 | clinicaltrials |
| NCT00005025 | Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | unknown | Phase 2 | — | John Stoddard Cancer Center at Iowa Methodist Medical CenterOTHER | 1 | Nov 6, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jan 12, 2015source: clinicaltrials